Sentiss
Bengaluru, India· Est.
Sentiss develops novel sustained‑release ocular therapies to address unmet retinal disease needs in emerging markets.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Sentiss develops novel sustained‑release ocular therapies to address unmet retinal disease needs in emerging markets.
Ophthalmology
Technology Platform
A proprietary biodegradable polymeric nanoparticle system for sustained intravitreal drug delivery, enabling reduced injection frequency and improved ocular bioavailability.
Opportunities
Expanding demand for affordable retinal disease therapies in India and potential partnerships with global ophthalmic pharma seeking cost‑effective solutions.
Risk Factors
Technology translation risk, regulatory approval uncertainty, and competition from established ophthalmic drug developers.
Competitive Landscape
Competes with multinational firms such as Novartis and Roche, as well as Indian companies like Sun Pharma, differentiating through a novel sustained‑release delivery platform.